X4 Pharmaceuticals (XFOR) Non-Current Assets (2017 - 2026)

X4 Pharmaceuticals (XFOR) has reported Non-Current Assets for 10 consecutive years, with $34.2 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Non-Current Assets rose 6.15% year-over-year to $34.2 million; the trailing twelve-month figure through Jun 2026 stood at $122.1 million (down 10.2% YoY), and the FY2025 full-year result was $28.9 million, down 15.72% from the prior year.
• Non-Current Assets improved to $34.2 million in Q2 2026 per XFOR's latest filing, from $28.3 million in the prior quarter.
• Across five years, Non-Current Assets topped out at $35.2 million in Q2 2024 and bottomed at $24.8 million in Q1 2024.
• Historically, Non-Current Assets has averaged $29.6 million across 5 years, with a median of $28.6 million in 2022.
• The sharpest annual moves came in 2022 and 2024: Non-Current Assets sank 30.46% in 2022, then jumped 38.44% in 2024.
• Over 5 years, Non-Current Assets stood at $26.9 million in 2022, then retreated by 6.42% to $25.2 million in 2023, then jumped by 36.1% to $34.3 million in 2024, then decreased by 15.72% to $28.9 million in 2025, then increased by 18.43% to $34.2 million in 2026.
• According to Business Quant data, Non-Current Assets over the past three periods registered $34.2 million, $28.3 million, and $28.9 million for Q2 2026, Q1 2026, and Q4 2025 respectively.